Literature DB >> 3509859

Pathogenesis of Rift Valley fever virus (RVFV) in inbred rats.

G W Anderson1, T W Slone, C J Peters.   

Abstract

The pathogenesis of Rift Valley fever in adult rats from 3 inbred strains (LEW, MAXX, WF) was investigated. WF rats all died by day 2 postinoculation with viral tissue titers reaching 9 log10 PFU/g. LEW and MAXX rats were resistant to liver disease, but fatal necrotising encephalitis developed in 16 and 44% of the rats, respectively. Detection of serum neutralising antibody on day 3 coincided with clearance of virus from serum and liver, although infectious virus was detected in spleen homogenates as late as day 19 postinfection. Viral titers in LEW and MAXX rats did not exceed 4.5 log10 PFU/g. Cyclophosphamide immunosuppression of LEW rats led to death 5-9 days postinfection; early patterns of viral replication were not affected, but continued growth in the liver resulted in fatal hepatitis. These animals could be protected by passive antibody therapy administered on days 2-5 postinfection to mimic the serum neutralising antibody pattern seen in unmanipulated infected LEW rats. Thus, RVF virus replication and spread is rapid in the WF rats tissues, whereas in LEW and MAXX rats viral growth is less due to an intrinsic mechanism which allows sufficient time for an immune response to terminate infection. A slightly diminished immune response may lead to the development of encephalitis more frequently in MAXX than LEW rats. These rat strains should be useful in elucidating those mechanisms of resistance which limit RVFV-induced hepatitis and encephalitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3509859     DOI: 10.1016/0882-4010(87)90126-4

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  24 in total

1.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

2.  The genetic basis for susceptibility to Rift Valley fever disease in MBT/Pas mice.

Authors:  S Tokuda; T Z Do Valle; L Batista; D Simon-Chazottes; L Guillemot; M Bouloy; M Flamand; X Montagutelli; J-J Panthier
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 3.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

4.  The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis.

Authors:  G W Anderson; T W Slone; C J Peters
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

5.  The S segment of Punta Toro virus (Bunyaviridae, Phlebovirus) is a major determinant of lethality in the Syrian hamster and codes for a type I interferon antagonist.

Authors:  Lucy A Perrone; Krishna Narayanan; Melissa Worthy; C J Peters
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  Experimental Rift Valley fever in rhesus macaques.

Authors:  C J Peters; D Jones; R Trotter; J Donaldson; J White; E Stephen; T W Slone
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

7.  Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA.

Authors:  John C Morrill; Tetsuro Ikegami; Naoko Yoshikawa-Iwata; Nandadeva Lokugamage; Sungyong Won; Kaori Terasaki; Aya Zamoto-Niikura; C J Peters; Shinji Makino
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

8.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

9.  Effect of macrophage source and activation on susceptibility in an age-dependent model of murine hepatitis caused by a phlebovirus, Punta Toro.

Authors:  P S Latham; S B Sepelak
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.